Loading
Latest filing published 13 Feb 2026 for Enanta Pharmaceuticals INC.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Brendan Luu (senior executive) discloses dealings in Enanta Pharmaceuticals Inc to SEC (Form 4). Over a trading history stretching from 19 November 2021 to 12 February 2026, the count stands at 22 filings.
No open-market purchase appears, only 3 sales worth €53k. The rest of the record consists of 19 share grants.
The newest entry dates from 13 February 2026: a share grant of €39k, in Enanta Pharmaceuticals Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations